ArticleInternational journal of oncology2012
Epidermal growth factor induces bladder cancer cell proliferation through activation of the androgen receptor.
Article in International journal of oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.
- Pooled it
- Observational
- DeepKEGG: a multi-omics data integration framework with biological insights for cancer recurrence prediction and biomarker discovery.Briefings in bioinformatics · 2024Article
- Review
- Functional characterization of the dimeric form of PDGF-derived fusion peptide fabricated based on theoretical arguments.Scientific reports · 2024Article
- Stratifying risk of disease in haematuria patients using machine learning techniques to improve diagnostics.Frontiers in oncology · 2024Article
- The androgen receptor in bladder cancer.Nature reviews. Urology · 2023Review
- Renal Cell Carcinoma as a Metabolic Disease: An Update on Main Pathways, Potential Biomarkers, and Therapeutic Targets.International journal of molecular sciences · 2022Review
- A robust signature of immune-related long non-coding RNA to predict the prognosis of bladder cancer.Cancer medicine · 2021Article
- Review
- The prognostic role of steroid hormone receptor signaling pathways in urothelial carcinoma.Translational cancer research · 2020Review
- Article
- Establishment of 2.5D organoid culture model using 3D bladder cancer organoid culture.Scientific reports · 2020Article
- Androgen receptor regulates ASS1P3/miR-34a-5p/ASS1 signaling to promote renal cell carcinoma cell growth.Cell death & disease · 2019Article
- Survival differences among patients with bladder cancer according to sex: Critical evaluation of radical cystectomy use and delay to treatment.Urologic oncology · 2017Article
- The expression of keratin 6 is regulated by the activation of the ERK1/2 pathway in arsenite transformed human urothelial cells.Toxicology and applied pharmacology · 2017Article
- Revealing protein networks and gene-drug connectivity in cancer from direct information.Scientific reports · 2017Article
- The role of the androgen receptor in ovarian cancer carcinogenesis and its clinical implications.Oncotarget · 2017Review
- Androgen Receptor Signaling in Bladder Cancer.Cancers · 2017Review
- Enzalutamide as an androgen receptor inhibitor prevents urothelial tumorigenesis.American journal of cancer research · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Androgen receptor (AR) signals have been suggested to contribute to bladder tumorigenesis and cancer progression. Activation of epidermal growth factor receptor (EGFR) also leads to stimulation of bladder tumor growth. However, crosstalk between AR and EGFR pathways in bladder cancer remains uncharacterized. We have recently shown that androgens activate the EGFR pathway in bladder cancer cells. The purpose of this study was to investigate the effects of EGF on AR activity in bladder cancer. EGF increased AR transcriptional activity by 1.2-, 1.9- and 2.0-fold in UMUC3, 5637-AR and J82-AR cell lines, respectively, over mock treatment and a specific EGFR inhibitor, PD168393, antagonized the EGF effect. Combined treatment of EGF and dihydrotestosterone (DHT) further induced AR transactivation while an AR antagonist, hydroxyflutamide (HF), abolished the effect of not only DHT but also EGF. In growth assays, EGF alone/DHT alone/EGF+DHT increased cell numbers by 16/12/19%, 6/14/18% and 30/12/38% in UMUC3-control-shRNA, 5637-AR and J82-AR, respectively, whereas the effects of EGF were marginal or less significant in UMUC3-AR-shRNA (8%) or AR-negative 5637-V (<1%) and J82-V (17%) cells. HF treatment at least partially counteracted the EGF effect on the growth of AR-positive cells. Western blotting demonstrated that EGF, especially in the presence of DHT, upregulated the expression of the p160 coactivator TIF2 and HF again blocked this stimulation. Co-immunoprecipitation revealed the association between AR and estrogen receptor (ER)-β or Src in UMUC3 cells and stronger associations with EGF treatment, implying the involvement of the AR/ER/Src complex in EGF-increased AR transactivation and cell growth. Current results, thus, suggest that EGF promotes bladder cancer cell proliferation via modulation of AR signals. Taken together with our previous findings, crosstalk between EGFR and AR pathways can play an important role in the progression of bladder cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.